Marrone Bio Innovations Inc. (NASDAQ:MBII) had its price objective boosted by Jefferies Group from $1.50 to $2.50 in a report released on Wednesday morning. The brokerage currently has a hold rating on the stock.
Separately, Zacks Investment Research cut shares of Marrone Bio Innovations from a hold rating to a sell rating in a research note on Thursday, November 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $5.50.
Shares of Marrone Bio Innovations (NASDAQ:MBII) opened at 2.42 on Wednesday. The stock’s market cap is $59.67 million. Marrone Bio Innovations has a 52-week low of $0.60 and a 52-week high of $2.79. The stock’s 50 day moving average price is $2.03 and its 200-day moving average price is $1.33.
Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.07. Marrone Bio Innovations had a negative return on equity of 2,083.14% and a negative net margin of 258.51%. On average, analysts predict that Marrone Bio Innovations will post ($1.17) earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Marrone Bio Innovations stock. Ardsley Advisory Partners bought a new stake in Marrone Bio Innovations Inc. (NASDAQ:MBII) during the third quarter, according to its most recent filing with the SEC. The fund bought 774,438 shares of the company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned approximately 3.15% of Marrone Bio Innovations as of its most recent SEC filing. 37.87% of the stock is owned by institutional investors.
About Marrone Bio Innovations